和美新_____肺肿瘤;_化疗;

和美新治疗小细胞肺癌的临床观察

http://www.100md.com 《新疆医科大学学报》 2005年第1期

和美新,,肺肿瘤;,化疗;,和美新,1资料与方法,2结果,3讨论,参考文献:

     摘要: 目的：观察和美新联合化疗治疗小细胞肺癌的疗效及毒性反应。方法： 52例患者均为病理确诊的小细胞肺癌。其中初治组32例，复治组20例，和美新2 mg 静脉点滴30 min(第1~4天)，顺铂30 mg/m2(第1~3天)，21 d为1个周期，平均使用2个周期。结果：初治组CR 7例，PR 15例，有效率68.8%，1年生存率36.3%；复治组CR 1例，PR 9例，有效率52.6%，1年生存率23.1%，两组有效率、1年生存率及毒副反应比较差异无统计学意义(P>0.05)。结论：和美新联合化疗治疗小细胞肺癌疗效好，毒副反应可耐受，主要毒性为骨髓毒性，非血液系统毒性较轻。

    关键词: 肺肿瘤; 化疗; 和美新

    Hycamtin in the treatment of nonsmall cell lung cancerLIU

    Chunling, JIAN Jiayu, SAN Li, et al

    (Depatment of Internal Medicine, Affiliated Tumor Hospital, Xinjiang Medical University,Urumqi 830011, China)

    Abstract: Objective: To discuss the therapeutic effect and toxicity of Hycamtin for nonsmall cell lung cancer patients. Methods: All these 52 patients received Hycamtin treatment combined of cisplatin: given Hycamtin at the dose of 2 mg per day four consecutive days and cisplatin at the dose of 30 mg/m2 per day for three days as one cycle and 21 days as one course. Average course was 2 cycles. Results: Among the primary arm, 7 patients showed CR, 15 patients showed PR, giving an effective rate of 68.6%, in the retreat arm, 1 patient showed CR, 9 patients showed PR, giving an effective rate of 52.6%. There was no significant difference. Conclusion: Hycamtin is indicated for nonsmall cell lung cancer giving tolerable toxicity. ......

百拇医药网 http://www.100md.com/html/DirDu/2005/11/05/79/37/01.htm

您现在查看是摘要页，全文长 6681 字符。